Further Developments towards a Minimal Potent Derivative of Human Relaxin-2

Thomas N.G. Handley, Praveen Praveen, Julien Tailhades, Hongkang Wu, Ross A.D. Bathgate, Mohammed Akhter Hossain

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Human relaxin-2 (H2 relaxin) is a peptide hormone with potent vasodilatory and anti-fibrotic effects, which is of interest for the treatment of heart failure and fibrosis. H2 relaxin binds to the Relaxin Family Peptide Receptor 1 (RXFP1). Native H2 relaxin is a two-chain, three-disulfide-bond-containing peptide, which is unstable in human serum and difficult to synthesize efficiently. In 2016, our group developed B7-33, a single-chain peptide derived from the B-chain of H2 relaxin. B7-33 demonstrated poor affinity and potency in HEK cells overexpressing RXFP1; however, it displayed equivalent potency to H2 relaxin in fibroblasts natively expressing RXFP1, where it also demonstrated the anti-fibrotic effects of the native hormone. B7-33 reversed organ fibrosis in numerous pre-clinical animal studies. Here, we detail our efforts towards a minimal H2 relaxin scaffold and attempts to improve scaffold activity through Aib substitution and hydrocarbon stapling to re-create the peptide helicity present in the native H2 relaxin.

Original languageEnglish
Article number12670
Number of pages9
JournalInternational Journal of Molecular Sciences
Volume24
Issue number16
DOIs
Publication statusPublished - Aug 2023

Keywords

  • 7BP
  • B7-33
  • B9-31
  • fibrosis
  • human relaxin-2
  • peptide synthesis
  • RXFP1

Cite this